New Drug Rheumatoid Arthritis - Kevzara Approved May 2017

In May, 2017 the FDA approved a new IL-6 antagonist to treat rheumatoid arthritis — Kevzara (sarilumab) .

Kevzara is from Regeneron and Sanofi. Regeneron is a NY based pharmaceutical compnay, Sanofi is a global life science company, the two collaborated in developing Kevzara.

Being an antagonist, it works to block IL-6, an inflammatory cytokine, so that the swelling and pain linked to rheumatoid arthritis can be improved. Kevzara (sarilumab) is used for the treatment of patients with moderate-to-severe rheumatoid arthritis, the new medicine specially work for people who don’t respond to or cannot tolerate one or more disease-modifying antirheumatic drugs (DMARDs). It can be used alone or in combination with methotrexate (MTX) or other conventional DMARDs.

In studies, the most common side effects linked with Kevzara included:

  • neutropenia
  • increased liver enzymes
  • injection site redness
  • upper respiratory infections
  • urinary tract infections.

In the MOBILITY study, treatment with Kevzara plus MTX reduced signs and symptoms, improved physical function, and demonstrated significantly less radiographic progression of structural damage, compared to placebo plus MTX.

Please consult your doctor if you feel this new drug may improve your RA condition.


* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.